- KR₩36tn
- KR₩39tn
- KR₩4tn
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares
Brief: Celltrion Announces U.S. Availability Of Avtozma® (Tocilizumab-Anoh) Subcutaneous (SC) Formulation
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists
Brief: Celltrion Inc U.S. Unit Celltrion Usa Signs Production Contract With Eli Lilly Worth 473 Million USD
Celltrion to invest up to $478 mln to expand US factory in response to tariffs
Brief: Celltrion To Cell 746 Million Won Worth Of Own Shares
Shares of Asian drugmakers drop after Trump threatens tariffs (updated)
South Korean shares set to snap 4-week rally on US tariff woes
Shares of South Korea’s drugmakers drop after Trump unveils tariffs
South Korean shares hit fresh record as chip, pharma stocks rally
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows (updated)
Celltrion unit pays $330 million for Eli Lilly production facility, filing shows
Brief: FDA Approves Expanded Indication For Avtozma® Intravenous Formulation In Cytokine Release Syndrome
South Korea's Celltrion says tapped to buy US pharma factory to offset tariff risk (updated)
South Korea's Celltrion says is preferred bidder to acquire pharma company to offset US tariff risk
Brief: Celltrion To Buy Back 100 Billion Won Worth Shares